computer generated randomisation sequences (Parexel Inc)
90
Structured Review
Parexel Inc
computer generated randomisation sequences
Computer Generated Randomisation Sequences, supplied by Parexel Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+generated+randomisation+sequences/randomization+envelopes/10__1002_slash_14651858__cd011535__pub3-5457-64-57
Average 90 stars, based on 1 article reviews
Computer Generated Randomisation Sequences, supplied by Parexel Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+generated+randomisation+sequences/randomization+envelopes/10__1002_slash_14651858__cd011535__pub3-5457-64-57
Average 90 stars, based on 1 article reviews
computer generated randomisation sequences - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Selection:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (p 278): "In reSURFACE 1, participants were randomly assigned (2:2:1) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo...In reSURFACE 2, participants were randomly assigned (2:2:1:2) to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg...Parexel International, the contract research organisation, generated computer generated randomisation sequences, and an interactive voice-response system and interactive web-response system was used by Parexel to allocate participants to groups. .. Randomised treatment assignments on day 1 were done by region" Comment: Probably done Allocation concealment (selection bias) Low risk Quote (p 278): "In reSURFACE 1, participants were randomly assigned (2:2:1) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo...In reSURFACE 2, participants were randomly assigned (2:2:1:2) to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg...Parexel International, the contract research organisation, generated Generated:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (p 278): "In reSURFACE 1, participants were randomly assigned (2:2:1) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo...In reSURFACE 2, participants were randomly assigned (2:2:1:2) to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg...Parexel International, the contract research organisation, generated computer generated randomisation sequences, and an interactive voice-response system and interactive web-response system was used by Parexel to allocate participants to groups. .. Randomised treatment assignments on day 1 were done by region" Comment: Probably done Allocation concealment (selection bias) Low risk Quote (p 278): "In reSURFACE 1, participants were randomly assigned (2:2:1) to tildrakizumab 200 mg, tildrakizumab 100 mg, or placebo...In reSURFACE 2, participants were randomly assigned (2:2:1:2) to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg...Parexel International, the contract research organisation, generated |
